# Study of Pembrolizumab, Carboplatin, Paclitaxel, and Radiation for the Treatment of Early-Stage Anal Cancer

> **NCT06493019** · PHASE2 · RECRUITING · sponsor: **Dustin Deming** · enrollment: 23 (estimated)

## Conditions studied

- Anal Cancer

## Interventions

- **DRUG:** Pembrolizumab
- **DRUG:** Paclitaxel
- **DRUG:** Carboplatin
- **RADIATION:** Radiation
- **DRUG:** Pembrolizumab

## Key facts

- **NCT ID:** NCT06493019
- **Lead sponsor:** Dustin Deming
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-09-30
- **Primary completion:** 2027-04-15
- **Final completion:** 2029-04-14
- **Target enrollment:** 23 (ESTIMATED)
- **Last updated:** 2026-03-23

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06493019

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06493019, "Study of Pembrolizumab, Carboplatin, Paclitaxel, and Radiation for the Treatment of Early-Stage Anal Cancer". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT06493019. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*